These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 24018020)

  • 41. Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis.
    Petrelli F; Coinu A; Cabiddu M; Ghilardi M; Vavassori I; Barni S
    Eur Urol; 2014 Feb; 65(2):350-7. PubMed ID: 23849998
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?
    Brant A; Kates M; Chappidi MR; Patel HD; Sopko NA; Netto GJ; Baras AS; Hahn NM; Pierorazio PM; Bivalacqua TJ
    Urol Oncol; 2017 Jan; 35(1):34.e17-34.e25. PubMed ID: 27639777
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Singapore Cancer Network (SCAN) Guidelines for Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer.
    Singapore Cancer Network (SCAN) Genitourinary Cancer Workgroup
    Ann Acad Med Singap; 2015 Oct; 44(10):415-20. PubMed ID: 26763059
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors.
    Angulo JC; Sanchez-Chapado M; Lopez JI; Flores N
    J Urol; 1996 Jun; 155(6):1897-902. PubMed ID: 8618282
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The current status of perioperative chemotherapy for invasive bladder cancer: a multiinstitutional retrospective study in Japan.
    Matsui Y; Nishiyama H; Watanabe J; Teramukai S; Ono Y; Ohshima S; Fujimoto K; Hirao Y; Fukushima M; Ogawa O
    Int J Clin Oncol; 2005 Apr; 10(2):133-8. PubMed ID: 15864700
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lymphovascular invasion and the presence of more than three tumors are associated with poor outcomes of muscle-invasive bladder cancer after bladder-conserving therapies.
    Zhang M; Tao R; Zhang C; Shen Z
    Urology; 2010 Oct; 76(4):902-7. PubMed ID: 20709377
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?
    Berg S; D'Andrea D; Vetterlein MW; Cole AP; Fletcher SA; Krimphove MJ; Marchese M; Lipsitz SR; Sonpavde G; Noldus J; Shariat SF; Kibel AS; Trinh QD; Mossanen M
    Cancer; 2019 May; 125(9):1449-1458. PubMed ID: 30620387
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pathological T0 Following Cisplatin-Based Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Network Meta-analysis.
    Kim HS; Jeong CW; Kwak C; Kim HH; Ku JH
    Clin Cancer Res; 2016 Mar; 22(5):1086-94. PubMed ID: 26503947
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Optimal Timing of Chemotherapy and Surgery in Patients with Muscle-Invasive Bladder Cancer and Upper Urinary Tract Urothelial Carcinoma.
    Tabayoyong W; Li R; Gao J; Kamat A
    Urol Clin North Am; 2018 May; 45(2):155-167. PubMed ID: 29650132
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reasons why not all Danish patients with muscle invasive bladder cancer receive neoadjuvant chemotherapy before radical cystectomy.
    Nielsen N; Wrist Lam G; Fabrin K; Holt P; Thind PO; Jensen JB
    Scand J Urol; 2019 Aug; 53(4):213-216. PubMed ID: 31174449
    [No Abstract]   [Full Text] [Related]  

  • 51. Systemic, perioperative management of muscle-invasive bladder cancer and future horizons.
    Funt SA; Rosenberg JE
    Nat Rev Clin Oncol; 2017 Apr; 14(4):221-234. PubMed ID: 27874062
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adjuvant chemotherapy for muscle-invasive bladder cancer.
    Sun W; Vaughn DJ
    Semin Urol Oncol; 2001 Aug; 19(3):186-93. PubMed ID: 11561986
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base.
    David KA; Milowsky MI; Ritchey J; Carroll PR; Nanus DM
    J Urol; 2007 Aug; 178(2):451-4. PubMed ID: 17561135
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinicopathological factors in bladder cancer for cancer-specific survival outcomes following radical cystectomy: a systematic review and meta-analysis.
    Zhang L; Wu B; Zha Z; Qu W; Zhao H; Yuan J
    BMC Cancer; 2019 Jul; 19(1):716. PubMed ID: 31324162
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
    Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adjuvant chemotherapy for bladder cancer-why does level 1 evidence not support it?
    Raghavan D; Bawtinhimer A; Mahoney J; Eckrich S; Riggs S
    Ann Oncol; 2014 Oct; 25(10):1930-1934. PubMed ID: 24569916
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adjuvant methotrexate, vinblastine and cisplatin chemotherapy for invasive transitional cell carcinoma: Taiwan experience.
    Wei CH; Hsieh RK; Chiou TJ; Chen KK; Chang LS; Chen PM
    J Urol; 1996 Jan; 155(1):118-21. PubMed ID: 7490806
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.
    Grossman HB; Natale RB; Tangen CM; Speights VO; Vogelzang NJ; Trump DL; deVere White RW; Sarosdy MF; Wood DP; Raghavan D; Crawford ED
    N Engl J Med; 2003 Aug; 349(9):859-66. PubMed ID: 12944571
    [TBL] [Abstract][Full Text] [Related]  

  • 59. FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy.
    Sung JY; Sun JM; Chang Jeong B; Il Seo S; Soo Jeon S; Moo Lee H; Yong Choi H; Young Kang S; Choi YL; Young Kwon G
    Urol Oncol; 2014 Jan; 32(1):49.e23-31. PubMed ID: 24360661
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adjuvant chemotherapy in muscle-invasive bladder carcinoma: a pooled analysis from phase III studies.
    Ruggeri EM; Giannarelli D; Bria E; Carlini P; Felici A; Nelli F; Gallucci M; Cognetti F; Pollera CF
    Cancer; 2006 Feb; 106(4):783-8. PubMed ID: 16419069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.